Mortality of ST-Elevation Myocardial Infarction (STEMI) in Mexico: Current Trends, Challenges, and Strategies for Improvement
Main Article Content
Abstract
ST-Elevation Myocardial Infarction (STEMI) remains a leading cause of cardiovascular mortality worldwide, with significant regional disparities. In Mexico, despite advances in healthcare systems and the availability of reperfusion therapies, STEMI continues to contribute substantially to cardiovascular-related deaths. This article reviews the mortality rates associated with STEMI in Mexico, focusing on epidemiological trends, barriers to optimal care, and regional healthcare inequalities. Key factors influencing outcomes include delayed diagnosis, limited access to percutaneous coronary intervention (PCI), socioeconomic determinants, and regional variability in healthcare infrastructure. Strategies to mitigate these challenges, such as strengthening prehospital care, expanding reperfusion networks, and addressing healthcare inequities, are discussed. This review underscores the urgent need for nationwide efforts to optimize STEMI management and reduce associated mortality.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Murray CJL, Lopez AD, Eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, 1996.
II. Jerjes-Sanchez C, Garcia BE, Sanchez CJR, Juarez U, Martinez-Sanchez C. Clinical characteristics, process of care, and outcomes among Mexican, Hispanic and Non-Hispanic white patients presenting with non-ST elevation acute coronary syndromes: data from RENASICA and CRUSADE registries. Arch Cardiol Mex. 2012;82:14-21.
III. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndrome in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-40.
IV. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL et al, for the TIMI investigatros. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
V. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al, for the GRACE investigators. A validated prediction model for all forms of acute coronary syndrome. JAMA. 2004;291:2727-33.
VI. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al, for the GRACE investigators. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177-89.
VII. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45.
doi: 10.1093/eurheartj/ehn416.
VIII. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Patients with ST-elevation myocardial infarction 2007 focused update of the ACC/AHA 2004 Guidelines for the Management. J Am Coll Cardiol. 2008;51:210-47.
IX. García CA, Jerjes-Sánchez C, Martínez-Bermúdez P, Azpiri-López JR, Autrey Caballero A, Martínez Sánchez C, et al. Renasica II. A Mexican registry of acute coronary syndromes. Arch Cardiol Mex. 2005;75:S18-30.
X. The ACCESS Investigators. Management of acute coronary syndromes in developing countries: ACCESS (ACute Coronary Events – a multinational Survey of current management Strategies) registry. Am Heart J. 2011;162:852-859.e22.
XI. [No authors listed]. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502-13.
XII. Alpert JS. Are data from clinical registries of any value? Eur Heart J. 2000; 21:1309-401.
XIII. Granger CB, Gersh BJ. Clinical trials and registries in cardiovascular disease: competitive or complementary? Eur Heart J. 2010; 31:520-1.
XIV. Gitt AK, Bueno H, Danchin N, Fox K, Hochadel M, Kearney P, et al. The role of cardiac registries in evidence based-medicine. Eur Heart J. 2010;31:525-9.
XV. Cohen MG, Roe MT, Mulgund J, Peterson ED, Sonel AF, Menon V, et al. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: Results from can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE). Am Heart J. 2006;152:110-7.
XVI. Center for Disease Control and Prevention. Use of race and ethnicity in public health surveillance. Summary of the CDC/ATSDR Workshop. MMWR Morb Mortal Wkly Rep. 1993;42 (No. RR-10): 1-17.